Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
36 hedge funds and large institutions have $6.86M invested in Novelion Therapeutics Inc. Common Shares in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 16 closing their positions.
27% less funds holding
Funds holding: 49 → 36 (-13)
37% less call options, than puts
Call options by funds: $31K | Put options by funds: $49K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
83% less capital invested
Capital invested by funds: $39.7M → $6.86M (-$32.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$1.07M |
| 2 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$891K |
| 3 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$196K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$54.8K |
| 5 |
VF
Virtu Financial
New York
|
+$33.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.49M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$3.03M |
| 3 |
Morgan Stanley
New York
|
-$1.84M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.35M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$1.31M |
NVLN Hedge Fund Activity: Q4 2018 in Review
36 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q4 2018, worth a combined $6.86M — down 83% from $39.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NVLN and 4 opened new positions — a net loss of 12 holders — while 10 trimmed existing stakes and 5 added.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $1.07M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.49M sold.
- 36 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q4 2018, down from 49 in Q3 2018.
- Funds reported $6.86M of Novelion Therapeutics Inc. Common Shares stock for Q4 2018, down 83% quarter-over-quarter.
- 4 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q4 2018 and 16 closed out, a net change of -12 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q4 2018 was Highbridge Capital Management, an estimated $1.07M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q4 2018 was Armistice Capital, an estimated $5.49M sold.
Based on aggregated 13F filings for Q4 2018.